Potentially Inappropriate Medication Use in Older Patients in 8 Central and Eastern Europe countries participating in the Horizon 2020 EUROAGEISM project: a narrative literature review (PE005)

Authors: J. Brkić, D. Fialová, Jindra Reissigová, P. Apostoli, V. Bobrova, A. Capiau, M. Držaić, S. Grešáková, I. Ince, I. Kummer, O. Ozkan, E. Puchoň, S. Sesto, K. Tachkov
Publication year: 2020
Publication type: Abstrakt
Periodical: International Journal of Clinical Pharmacy
Bibliographic citation: BRKIĆ, J., FIALOVÁ, D., REISSIGOVÁ, Jindra, APOSTOLI, P., BOBROVA, V., CAPIAU, A., DRŽAIĆ, M., GREŠÁKOVÁ, S., INCE, I., KUMMER, I., OZKAN, O., PUCHOŇ, E., SESTO, S., TACHKOV, K. Potentially Inappropriate Medication Use in Older Patients in 8 Central and Eastern Europe countries participating in the Horizon 2020 EUROAGEISM project: a narrative literature review (PE005). International Journal of Clinical Pharmacy. 2020, 42(1), 233-234. ISSN 2210-7703. E-ISSN 2210-7711
Dostupné z: doi:10.1007/s11096-019-00945-w
DOI: 10.1007/s11096-019-00945-w
ID: 524867

Abstract

BACKGROUND AND OBJECTIVE: Potentially Inappropriate Medication (PIM) use is highly prevalent among older adults, but studies on this topic from Central and Eastern Europe (CEECs) are rare. Therefore, the focus of the Horizon 2020 EUROAGEISM FIP7 project (2017–2021) is to describe PIM use in CEECs in comparison to Western Europe and Asian countries (Belgium, Spain, Ireland, India, and the United Arab Emirates). The objective of our study was to summarize existing evidence on PIM use (prevalence and risk factors) in CEECs. SETTING AND METHOD: The last search of SCOPUS and MEDLINE databases was conducted in April 2019. We included full-text articles on the prevalence of PIM use in older adults (60 +) in different settings of care in 8 CEECs participating in the Horizon 2020 EUROAGEISM FIP7 project (Albania-(AL), Bulgaria-(BG), Croatia-(HR), Czech Republic-(CZ), Estonia-(EE), Lithuania-(LT), Serbia-(RS) and Slovakia-(SK)). We excluded studies: measuring the prevalence of PIM use as an outcome of the intervention, focusing only on a specific patient group (e.g. palliative patients), disorder or medication class. MAIN OUTCOMES MEASURE: PIM prevalence and risk factors. RESULTS: Of 146 records only 14 studies met the inclusion criteria. The majority of studies were published in HR (5) and no studies in BG and EE. Prevalence of PIM use ranged: 20.0%(SK)–68.8%(HR) in acute care, 22.7%(CZ)–62.4%(HR) in outpatient care and 15.7%(CZ)–50.5%(RS) in community-dwelling older adults. Only one study was conducted in long-term care—34.3%(SK). The most frequently identified factor for PIM use was the increasing number of medications (OR range 1.4–68.0). CONCLUSION: The lack of evidence on PIM use in CEECs is substantial and contributes to slower development of clinical pharmacy services. Planned large prospective data collection and analyses describing aspects of PIM use and its´ risk factors in different settings of care (Horizon 2020 EUROAGEISM FIP7 project) could stimulate better prescribing and clinical pharmacy development in CEECs.